Retatrutide (RETA): Triple Receptor Agonist Research Overview

Published: May 2026

Retatrutide (research code LY3437943) is an investigational acylated synthetic peptide engineered as a single-molecule agonist at three receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). The molecule was developed at Eli Lilly and described by Coskun and colleagues in 2022, who reported a 39-amino-acid peptide built on a GIP-based backbone and modified with a fatty-acid (C20 diacid) side chain that promotes albumin binding and extends the plasma half-life enough to support once-weekly administration in research settings. It carries CAS number 2381089-83-2, a molecular formula of C₂₂₁H₃₄₂N₄₆O₆₈, and a molecular weight near 4,731 g/mol. As the first triple incretin-glucagon receptor agonist to advance into human clinical study, retatrutide has become a reference compound in preclinical and mechanistic research on multi-receptor pharmacology. It sits within the broader incretin class described in the GLP-1 receptor agonists research overview.

Molecular Profile

Discovery and Molecular Design

Retatrutide originated from a medicinal-chemistry program at Eli Lilly aimed at combining the actions of three metabolic receptors in one peptide. Coskun et al. (2022) published the discovery account in Cell Metabolism, describing how the peptide was engineered on a GIP-based scaffold and tuned so that its in vitro activity at GCGR and GLP-1R is balanced, with comparatively greater activity at GIPR. The acylation strategy, attachment of a C20 fatty-diacid moiety through a linker, promotes reversible albumin binding that slows renal clearance and supports once-weekly dosing intervals in animal pharmacokinetic studies.

The design rationale rests on a longstanding question in incretin research: whether a single peptide can recruit three distinct receptor systems without the off-target liabilities of administering separate agonists. Coskun and colleagues reported the relative potencies of retatrutide at each receptor and characterized its pharmacokinetic profile in preclinical species, work that established the molecule as a tool for studying how simultaneous, ratio-controlled receptor engagement differs from monoagonist or dual-agonist pharmacology.

Triple Receptor Agonism and the Glucagon Receptor

The three receptors retatrutide targets are all class B G protein-coupled receptors, and each couples primarily to Gαs, raising intracellular cyclic adenosine monophosphate (cAMP) on activation. GLP-1R and GIPR signaling has been examined extensively in the incretin literature reviewed by Müller et al. (2019) in Molecular Metabolism, where GLP-1R activation in pancreatic beta cells potentiates glucose-dependent insulin secretion and GIPR contributes parallel insulinotropic and adipose-tissue effects. The third target, GCGR, distinguishes retatrutide from dual agonists and from the GLP-1R monoagonists that preceded it.

Glucagon receptor pharmacology has been studied in the context of energy expenditure. Preclinical work indicates that GCGR activation in hepatocytes promotes fatty-acid oxidation and in brown adipose tissue is associated with thermogenic activity, mechanisms that operate on the energy-output side of metabolic balance rather than the energy-intake side engaged by GLP-1 and GIP signaling. The mechanistic hypothesis behind triple agonism, examined in the rodent studies discussed below, is that adding GCGR activity to incretin receptor engagement recruits an additional pathway in models of body-composition research.

Structural Pharmacology Research

How a single peptide accommodates three related but distinct receptors is a structural-biology question that has been addressed directly. Li et al. (2024) reported cryo-electron microscopy structures of retatrutide in complex with GLP-1R, GIPR, and GCGR in Cell Discovery, resolving the peptide-receptor interfaces for all three targets. The structures show how conserved and variable residues along the retatrutide sequence engage the orthosteric binding pockets of each receptor and how the peptide adopts compatible conformations across the three complexes.

These structural data provide a molecular basis for the tuned potency ratios reported in the discovery work. By mapping which residues drive recognition at each receptor, the Li study gives researchers a framework for interpreting structure-activity relationships across the incretin-glucagon multi-agonist series and for understanding why specific sequence modifications shift the balance of activity among GIPR, GLP-1R, and GCGR.

Preclinical Metabolic Studies in Rodent Models

The body-composition and metabolic effects of retatrutide were characterized in animal models before clinical study. Coskun et al. (2022) reported that administration to obese mice reduced body mass and improved glycemic measures, and that the reduction in body mass was associated with GCGR-mediated increases in energy expenditure layered onto the food-intake reduction attributed to GIPR and GLP-1R signaling. A single dose produced effects on body mass that persisted for several weeks in these models, consistent with the extended exposure conferred by acylation.

This rodent work builds on a lineage of multi-agonist studies. Knerr et al. (2022) reported in Molecular Metabolism that next-generation GLP-1/GIP/glucagon triple agonists normalized body mass in obese mice, with the glucagon-receptor component contributing additional body-mass lowering beyond GLP-1R agonism and GLP-1R/GIPR co-agonism at matched food intake. The convergent finding across these independent rodent programs, that GCGR engagement adds an energy-expenditure dimension to incretin pharmacology, frames much of the current preclinical interest in retatrutide.

Origins in Incretin Co-Agonist Research

Retatrutide is the product of more than a decade of peptide-engineering research on combined receptor agonism. Pocai et al. (2009) reported in Diabetes that a unimolecular GLP-1/glucagon receptor dual agonist reversed obesity in mice, an early demonstration that combining incretin and glucagon signaling in one peptide produced metabolic effects in animal models that neither activity achieved alone. This established the dual-agonist concept that later expanded toward triple agonism.

The dual-incretin branch of this research was advanced by Finan et al. (2013), who described in Science Translational Medicine a unimolecular GLP-1/GIP co-agonist with metabolic activity across rodent, monkey, and early human studies. Finan et al. (2015) extended the strategy in Nature Medicine with a rationally designed monomeric peptide triagonist that addressed obesity and diabetes endpoints in rodents, providing the proof of concept for single-molecule engagement of three receptors that retatrutide later realized in a clinically advanced form.

Clinical Research Context

Retatrutide has entered human clinical investigation, and findings from those studies are noted here as detached factual research within the incretin-glucagon field. Jastreboff et al. (2023) reported a phase 2, double-blind, randomized, placebo-controlled study of subcutaneous retatrutide in The New England Journal of Medicine, administering once-weekly doses over 48 weeks in the defined trial cohort. The investigators reported changes in body mass across dose groups relative to placebo, and gastrointestinal events consistent with the broader incretin pharmacology were the most commonly recorded findings.

These clinical observations are read in this research context against the receptor-level and animal-model data, not as outcomes available outside a controlled investigational setting. Phase 3 clinical investigations of retatrutide are ongoing, and the relative contribution of each of the three receptor targets to the measured effects in human physiology remains an open question that connects the clinical record back to the mechanistic and structural studies described above.

Key Published References

1. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234–1247.e9. PMID: 35985340
2. Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discov. 2024;10(1):77. PMID: 39019866
3. Knerr PJ, Mowery SA, Douros JD, et al. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Mol Metab. 2022;63:101533. PMID: 35809773
4. Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27–36. PMID: 25485909
5. Finan B, Ma T, Ottaway N, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;5(209):209ra151. PMID: 24174327
6. Pocai A, Carrington PE, Adams JR, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes. 2009;58(10):2258–2266. PMID: 19602537
7. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130. PMID: 31767182
8. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514–526. PMID: 37366315

Product Availability

Retatrutide (RETA) is available for qualified research applications through White Market Peptides: RETA 10 mg: Research Grade.